Sensorion Announces SENS-601 Program Day Focused on GJB2 Gene Therapy for Hearing Loss
Sensorion has announced registration details for its upcoming SENS-601 Program Day on September 22, 2026, which will spotlight the science, patient population, and clinical trial design for its lead GJB2 gene therapy candidate. The event will feature key insights from company leadership and clinical experts regarding the HearConnex trial aimed at addressing hereditary hearing loss.